ClinicalTrials.gg
RecruitingNCT05942001Updated Aug 31, 2026

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Phase 1 interventional study of HRS-5041 and Docetaxel injection in Advanced Prostate Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 14 open to participants now, 17 under way, 4 of them phase 3. Prostatic Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
12th of 31
100 · median 69
Started
2023
with 3 others
Phase 1
14 of 31
6 open now
Primary completion
2026-09
later than 6 of 16 live
Registered
16th of 31
by date

Among the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 12th largest by planned enrollment, is one of 4 that started in 2023, is one of 14 in phase 1, reaches primary completion later than 6 of the 16 other live ones, and was the 16th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of HRS-5041 in phase II study.

03

Conditions studied

  • Advanced Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written .
  2. Age 18-80 years old, gender unlimited.
  3. The physical status score of the Eastern Tumor Cooperative Group () was 0 \~ 1.
  4. Predicted survival ≥12 weeks.
  5. Histological or cytological confirmed adenocarcinoma of the prostate.
  6. Patients progressed on taxane chemotherapy and at least one prior secondary hormonal therapy.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with an androgen receptor (AR) degrader.
  2. Plan to receive any other antitumor therapy during this trial.
  3. Receiving other drugs or treatments that are not on the market within 4 weeks prior to the initial administration of the study.
  4. Patients with known .
  5. Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    HRS-5041

    Drug: HRS-5041

  • Active comparator
    Docetaxel Injection + Prednisone Acetate Tablets group

    Drug: Docetaxel injection · Drug: Prednisone Acetate Tablets

  • Active comparator
    Abiraterone Acetate Tablets + Prednisone Acetate Tablets group

    Drug: Abiraterone acetate tablets · Drug: Prednisone Acetate Tablets

  • Active comparator
    Enzalutamide Soft Capsules group

    Drug: Enzalutamide Soft Capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Time frame: Up to 28 days

  2. Maximum tolerated dose (MTD)

    Time frame: Up to 28 days

  3. Recommended Phase 2 Dose (RP2D) of HRS-5041

    Time frame: Up to 28 days

Secondary outcomes

  1. Number of participants with adverse events (AEs) evaluated using the NCI CTCAE v5.0 criteria

    Time frame: From the time of consent at screening until 30 days after the subject discontinues study treatment, up to 2 years

  2. Pharmacokinetics - Area under the plasma concentration time curve (AUC)

    Time frame: 12 weeks

  3. Pharmacokinetics - Maximum plasma concentration (Cmax)

    Time frame: 12 weeks

  4. Pharmacokinetics - Time to Cmax (Tmax)

    Time frame: 12 weeks

  5. Prostate Specific Antigen (PSA) decline of ≥ 50% from baseline (PSA50)

    Time frame: 24 months

  6. PSA Progression Free Survival (PFS)

    Time frame: 24 months

  7. Objective soft tissue response defined by complete response (CR) or partial response (PR) per Prostate Cancer Clinical Trials Working Group 3 (PCWG3)

    Time frame: 24 months

  8. Radiographic progression free survival (rPFS)

    Time frame: 24 months

  9. Overall survival (OS)

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Sep 2026, 37 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 37 months is close to that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2023
First posted
Jul 12, 2023
StartActual
Aug 3, 2023
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05942001
Responsible party
Sponsor
First posted
Jul 12, 2023
Start date
Aug 3, 2023
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Aug 31, 2026

Study contacts

Suyu Fan
Contact
suyu.fan@hengrui.com
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-5041

Start the discussion